What are the best pharmacologic options for treating insomnia (sleep onset and maintenance)?

Best Pharmacological Options for Insomnia

For sleep onset and maintenance insomnia in adults, eszopiclone (2-3 mg) or zolpidem (10 mg) are the best first-line pharmacological options, with suvorexant as an alternative for sleep maintenance problems specifically. These agents have the strongest evidence base with low-to-moderate quality data showing small but meaningful improvements in sleep outcomes 1.

Algorithmic Approach to Medication Selection

For Sleep Onset Insomnia (Difficulty Falling Asleep):

• First choice: Zolpidem 10 mg or eszopiclone 2-3 mg 1
• Alternative options: Zaleplon 10 mg, triazolam 0.25 mg, temazepam 15 mg, or ramelteon 8 mg 1

For Sleep Maintenance Insomnia (Difficulty Staying Asleep):

• First choice: Suvorexant (10-20 mg) or doxepin (3-6 mg) 1
• Alternative options: Eszopiclone 2-3 mg, zolpidem 10 mg, or temazepam 15 mg 1

For Both Sleep Onset AND Maintenance:

• First choice: Eszopiclone 2-3 mg or zolpidem 10 mg 1
• Alternative: Temazepam 15 mg 1

Evidence Quality and Nuances

The 2017 American Academy of Sleep Medicine guidelines 1 provide the most comprehensive framework, though all recommendations carry only WEAK strength due to predictable GRADE methodology limitations (funding sources, publication bias, small trial numbers, and data heterogeneity). This does not mean these medications are ineffective—rather, it reflects the inherent challenges in insomnia research.

The 2016 American College of Physicians evidence report 2 corroborates these findings, noting that eszopiclone, zolpidem, and suvorexant improved short-term global and sleep outcomes compared to placebo, though absolute effect sizes were small. Critically, this review found insufficient or low-strength evidence for benzodiazepine hypnotics, melatonin agonists, and antidepressants.

Medications to AVOID

Do NOT use the following agents for insomnia treatment 1:

• Trazodone (50 mg) - insufficient efficacy despite widespread off-label use
• Diphenhydramine - anticholinergic risks, especially in older adults
• Melatonin (over-the-counter formulations) - insufficient evidence for insomnia disorder
• Tiagabine - harms outweigh benefits
• Tryptophan and valerian - insufficient evidence

Critical Safety Considerations

Serious Harms to Monitor:

The FDA and observational studies 2 have identified important risks:

• Cognitive and behavioral changes, including next-day driving impairment
• Increased risk of dementia, fractures, and major injury with chronic hypnotic use
• Dose reduction required for women and older adults due to altered pharmacokinetics

Duration of Treatment:

• Short-term use (≤4 weeks): Benzodiazepines, benzodiazepine receptor agonists (Z-drugs), and low-dose sedating antidepressants 3
• Longer-term use (up to 3 months or more): Orexin receptor antagonists (suvorexant, daridorexant) have better evidence for extended use 3, 4
• Prolonged-release melatonin: Only for patients ≥55 years, up to 3 months 3

Special Populations

Older Adults (>65 years):

Preferred agents 5:

• Low-dose doxepin (3-6 mg)
• Ramelteon (8 mg)
• Dual orexin receptor antagonists (suvorexant)
• Avoid benzodiazepines and Z-drugs when possible due to fall risk, cognitive impairment, and fracture risk

When Comorbidities Exist:

While evidence is limited, certain medications may address both insomnia and comorbid conditions 4:

• Depression: Low-dose doxepin, mirtazapine (though not recommended as primary insomnia treatment)
• Neuropathic pain: Gabapentin or pregabalin (off-label, limited evidence)

Common Pitfalls to Avoid

1. Using trazodone as first-line therapy - Despite its popularity, guidelines explicitly recommend against it 1
2. Prescribing over-the-counter antihistamines long-term - Anticholinergic burden accumulates, particularly problematic in older adults
3. Failing to consider cognitive behavioral therapy for insomnia (CBT-I) - This remains the gold standard and should be offered alongside or before pharmacotherapy 3
4. Not adjusting doses in women and elderly - FDA specifically advises dose reductions in these populations 2
5. Continuing benzodiazepines/Z-drugs indefinitely - These should be time-limited; consider switching to orexin antagonists for longer-term needs 6

Emerging Evidence

The 2023 European Insomnia Guideline 3 and recent reviews 7, 4 highlight orexin receptor antagonists (suvorexant, lemborexant, daridorexant) as having potentially fewer adverse effects than traditional GABA-ergic agents, including lower dependence liability. Daridorexant can be used for periods up to 3 months or longer 3, making it preferable when extended treatment is anticipated.

Practical Implementation

Start with the medication that matches the specific insomnia phenotype (onset vs. maintenance), use the evidence-based doses listed above, limit benzodiazepines/Z-drugs to short-term use, and strongly consider orexin antagonists when treatment beyond 4 weeks is needed. Monitor for cognitive impairment, falls, and next-day sedation at every follow-up visit.